MedTrace Logo

Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism

NCT07399977 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 259

Last updated 2026-05-05

No results posted yet for this study

Summary

The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.

Conditions

Interventions

DIAGNOSTIC_TEST

MSK-ACCESS

MSK-ACCESS is a ctDNA sequencing assay

DIAGNOSTIC_TEST

ctDNA/VTE Risk Score:

Machine learning Venous Thromboembolism/VTE risk score mode

Sponsors & Collaborators

Principal Investigators

  • Justine Jee, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-30
Primary Completion
2030-01-30
Completion
2030-01-30
FDA Device
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07399977 on ClinicalTrials.gov